Clear Street initiated coverage of Equillium (NASDAQ: EQ) with a “buy” rating and price target of $9.00. The stock closed at $2.47 on July 20.
Equillium is a clinical-stage biotechnology company developing therapies that restore immune homeostasis across inflammatory diseases. Its lead program, EQ504, is a colon-targeted oral AhR modulator being developed for ulcerative colitis (UC), designed to restore epithelial barrier function and mucosal immune homeostasis while minimizing systemic exposure. EQ504 has completed IND-enabling studies and is expected to enter a P1 proof-of-mechanism study in healthy volunteers, followed by clinical evaluation in UC. The company is also developing EQ302, an oral dual IL-15/IL-21 inhibitor for celiac disease and other immune-mediated GI disorders.
Analyst Kaveri Pohlman, PhD, writes, “EQ504 has the potential to break the current efficacy ceiling, supported by its pleiotropic biology, which overlaps with obefazimod’s miR-124–driven mechanism that underpinned impressive P3 UC outcomes, and by its ability to modulate multiple commercially validated cytokines (TNF-α, IL-23, IL-12). Its colon-targeted formulation confers an added safety margin, strengthening the case for future combination strategies and making its overall profile particularly attractive.”
“EQ504’s novel target also facilitates drug-switching from currently approved agents; importantly, it is “novel but not untested,” as VTAMA’s approval in mechanistically similar diseases—AD (a Th2-driven inflammatory disease, analogous to UC) and PsO (a Th1/Th17-driven autoimmune disease, analogous to CD)—strongly reinforces EQ504’s potential in IBD. Moreover, direct, encouraging clinical data from the AhR agonist Indigo naturalis across multiple US and ex-US trials further de-risk the UC program,” she adds.
With respect to valuation, Dr. Pohlman writes, “We forecast ~$2.0B in risk-adjusted WW peak sales for EQ504 in UC (55% POS). Our 12-month PT of $9 per share is derived from a DCF analysis using a 14% discount rate and 0.5% terminal growth. While EQ’s estimated WACC is 5.86% (FactSet, 7/6/26), we apply a materially higher rate to reflect development, regulatory, and competitive risk given EQ504’s early stage. The 0.5% terminal-growth assumption further captures the company’s capacity to generate additional assets beyond EQ504 and EQ302 from its acquired multi-targeted peptide-therapeutic platform.”
